The cGAS–STING pathway as a therapeutic target in inflammatory diseases

Alexiane Decout1, Jason D. Katz2, Shankar Venkatraman2 and Andrea Ablasser3

Abstract | The cGAS–STING signalling pathway has emerged as a key mediator of inflammation in the settings of infection, cellular stress and tissue damage. Underlying this broad involvement of the cGAS–STING pathway is its capacity to sense and regulate the cellular response towards microbial and host-derived DNAs, which serve as ubiquitous danger-associated molecules. Insights into the structural and molecular biology of the cGAS–STING pathway have enabled the development of selective small-molecule inhibitors with the potential to target the cGAS–STING axis in a number of inflammatory diseases in humans. Here, we outline the principal elements of the cGAS–STING signalling cascade and discuss the general mechanisms underlying the association of cGAS–STING activity with various autoinflammatory, autoimmune and degenerative diseases. Finally, we outline the chemical nature of recently developed cGAS and STING antagonists and summarize their potential clinical applications.

The detection of foreign DNA serves as a crucial element of immunity in many organisms. In mammalian cells, this task is contributed in large part by the cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway, which has emerged as a critical mechanism for coupling the sensing of DNA to the induction of powerful innate immune defence programmes1. Within this pathway, the binding of cGAS to double-stranded DNA (dsDNA) allosterically activates its catalytic activity and leads to the production of 2′,3′ cyclic GMP–AMP (cGAMP), a second messenger molecule and potent agonist of STING2–8. A salient feature of the cGAS–STING pathway, which sets it apart from several other innate immune signalling mechanisms, is that its activation is triggered by a fundamental element of life (namely DNA) and, therefore, lacks any pathogen-specific attributes9. For this reason, cGAS recognizes a broad repertoire of DNA species of both foreign and self origin. Today, our understanding of the diverse functions of the cGAS–STING pathway in host immunity has become clearer, and multiple examples highlight the protective effects of this pathway during infection. Recent studies showing that the cGAS–STING system arose from an ancient bacterial anti-phage mechanism underscore this notion10,11. Growing evidence has indicated, however, that dysregulation of this highly versatile innate immune sensing system can disrupt cellular and organisal homeostasis by fuelling aberrant innate immune responses associated with a number of pathologies1. The parameters that dictate host-protective versus pathogenic activity are still being unfolded, but it appears that the intensity and chronicity of cGAS–STING signalling are major determinants in most cases. In light of this, efforts have been undertaken or are still under way to define strategies that allow selective modulation of cGAS–STING activity in various disease settings12,13.

We note that there are major drug discovery efforts currently under way to identify and translate agonists of the cGAS–STING pathway as vaccine adjuvants or as anticancer immunostimulatory agents, and these topics have been extensively covered in recent reviews14,15. By contrast, in this Review, we particularly focus on new developments concerning the role of the cGAS–STING pathway as a major driver of inflammatory diseases. We briefly summarize the current state of understanding of signalling through the cGAS–STING pathway, outline molecular mechanisms that trigger cGAS–STING pathway activity in distinct pathophysiological contexts, and analyse its involvement in preclinical models of disease. Drawing on recent advances in understanding of the cGAS–STING pathway structure and regulation, we examine pharmacological intervention strategies that target this pathway and discuss their therapeutic potential in the treatment of inflammatory and autoinflammatory diseases.

Overview of the cGAS–STING pathway

The synthesis of cGAMP is considered the crucial first step that sets in motion cGAS-mediated antiviral effects in various species3–8. In mammals, cGAS catalytic activity is triggered through interactions with dsDNA,
a process that through extensive structural and biochemical studies is now understood in detail\(^{19-20}\). In brief, the C-terminal part of human cGAS (h-cGAS) harbouring the nucleotidetransferase domain (the catalytic part) contains positively charged DNA-binding sites, one primary site and two additional sites, which bind the sugar–phosphate backbone of DNA. DNA binding to the primary site, the so-called A-site, induces conformational changes in the protein that rearrange the catalytic pocket of the enzyme to allow for an optimal interaction with the substrates ATP and GTP, whereas DNA binding to the juxtaposed B-site is crucial for the formation of the core 2:2 cGAS DNA complex — the minimal active enzymatic unit. On long dsDNA molecules, cGAS dimers arrange themselves into ladder-like networks and phase-separated organelles\(^{11,22}\). The formation of these spatially restricted higher-order cGAS–DNA assemblies on longer stretches of DNA is considered critical for triggering biological effects\(^{23}\). This mode of activation offers an important inbuilt safeguard mechanism for living cells: namely, that cGAS signalling can only be initiated when longer stretches of dsDNA are available to surpass a certain signalling threshold. By contrast, spurious activation of cGAS on limited and short dsDNA is prevented.

cGAMP is then detected by the endoplasmic reticulum (ER) membrane protein STING\(^{24}\). STING is composed of a short cytosolic N-terminal segment, a four-span transmembrane domain, a connector region and a cytosolic ligand-binding domain (LBD) on which a C-terminal tail (CTT) is appended. Already in the apo-form (that is, in the absence of a ligand), STING forms a domain-swapped homodimer, which on binding to cGAMP undergoes extensive conformational rearrangements, including an untwisting (180° rotation) of the LBD, an inward rotation of the LBD and the formation of an ordered β-sheet that covers the LBD\(^{25-30}\). Together, these changes assist in side-by-side oligomerization of STING dimers\(^{30}\). Oligomerization is further fostered by disulfide bridges spanning separate STING dimers as well as by palmitoylation of cysteine residues, C88 and C91 (Ref.\(^{34}\)). Thus, the oligomerized STING dimers form the activated STING unit capable of initiating effector functions. It is interesting to note that canonical cyclic dinucleotides — as well as a certain class of other interferon-stimulated genes (ISGs), is by far the best-understood process controlled by cGAS–STING activation. The CTT of STING first recruits TBK1 through a conserved PLPLRT/SD amino acid binding motif, which promotes dimerization-mediated TBK1 autophosphorylation\(^{43,44}\). Activated TBK1, in turn, phosphorylates STING at Ser366 (unless otherwise indicated, we refer to the human protein sequence) in the CTT, which is part of a PLxIS motif (in which p represents the hydrophilic residue, x represents any residue and S represents the phosphorylation site) and which allows the STING–TBK1 complex to recruit IRF3 (Ref.\(^{45}\)). TBK1 then phosphorylates IRF3, enabling its dimerization, nuclear translocation and target gene induction. In addition to type I interferons and ISGs, IRF3 activity is also required for the induction of many other target genes, including genes encoding inflammatory cytokines (such as IL6 and IL12)\(^{46}\). Not surprisingly, the IRF3-controlled transcriptional output varies considerably depending on the cell type under study, the STING trigger used and the exact in vivo context. Crucially, the previously mentioned oligomerization of

**Effects of cGAS–STING pathway activation**

Throughout evolutionary history, activation of the cGAS–STING pathway appears to have served to protect against viral infection and is associated with an anti-viral cellular programme\(^{40}\). In human and mouse cells, the most prominent downstream effector function of cGAMP signalling is the de novo synthesis of antiviral type I interferons and related gene products, which are generally assumed to account for most of the pathway’s antiviral functions\(^{40}\). However, the cGAS–STING pathway is also present in prokaryotes and in species such as the sea anemone *Nematostella vectensis* and the fruit fly *Drosophila melanogaster*, which do not encode type I interferons\(^{41,46}\). Thus, cGAS–STING originally relied on more evolutionarily ancient antiviral defence strategies, which are still functional within human cells and are highly significant for various biological consequences of the cGAS–STING pathway (Fig. 2).

**Control of transcriptional responses by cGAS–STING**

The activation of interferon regulatory factor 3 (IRF3) and its induction of type I interferons and other interferon-stimulated genes (ISGs), is by far the best-understood process controlled by cGAS–STING activation. The CTT of STING first recruits TBK1 through a conserved PLPLRT/SD amino acid binding motif, which promotes dimerization-mediated TBK1 autophosphorylation\(^{43,44}\). Activated TBK1, in turn, phosphorylates STING at Ser366 (unless otherwise indicated, we refer to the human protein sequence) in the CTT, which is part of a PLxIS motif (in which p represents the hydrophilic residue, x represents any residue and S represents the phosphorylation site) and which allows the STING–TBK1 complex to recruit IRF3 (Ref.\(^{45}\)). TBK1 then phosphorylates IRF3, enabling its dimerization, nuclear translocation and target gene induction. In addition to type I interferons and ISGs, IRF3 activity is also required for the induction of many other target genes, including genes encoding inflammatory cytokines (such as IL6 and IL12)\(^{46}\). Not surprisingly, the IRF3-controlled transcriptional output varies considerably depending on the cell type under study, the STING trigger used and the exact in vivo context. Crucially, the previously mentioned oligomerization of
STING is highly significant for these events to occur, because owing to steric constraints, a given STING dimer cannot serve simultaneously as the docking site for TBK1 and its substrate. Consistently, interfering with STING oligomerization significantly reduces its ability to promote type I interferon upregulation. Undoubtedly, type I interferons are critical for STING’s antiviral activity. However, STING’s role in immunity is not solely governed by type I interferon signalling. A case in point has been made recently by the demonstration that mice harbouring a mutation in STING that selectively impacts its type I interferon-inducing capacity are still protected against herpes simplex virus 1 (HSV-1) infection, whereas mice with complete deficiency for STING are susceptible. Another major signalling module used by STING is NF-κB-mediated transcriptional activation. This STING-dependent activity does not fully depend on the CTT. As such, although TBK1 itself can promote NF-κB activation, it is not required and can be compensated for by IKKε upstream of TAK1 and IKK complexes, at least in certain cell types. Consistent with this observation, ancestral STING homologues in insects and early metazoans completely lack the CTT signalling.
element, but can still function in host defence by promoting NF-κB responses, arguing that this constitutes a possible archetypal STING-dependent antimicrobial mechanism. Interestingly, certain vertebrate fish species, such as zebrafish and other ray-finned fish species, have acquired additional motifs appended to the CTT to further boost NF-κB activation via the recruitment of TRAF6 (REF. 49). Although STING-mediated NF-κB transcription appears to be a highly conserved and relevant downstream activity, how STING interacts with NF-κB pathway components at a molecular resolution still remains obscure. Stimulation of cGAS–STING also promotes non-canonical NF-κB responses through the triggering of p52–RELB nuclear translocation51,52. This signalling output, which limits type I interferons and canonical NF-κB, emerges as a critical negative regulator of STING effector mechanisms, which can have important biological consequences with regard to cancer immune escape and metastasis (see below). In certain contexts, cGAS–STING signalling may additionally

**Fig. 2 | cGAS–STING effector mechanisms and intercellular cGAMP transmission.** a | Stimulator of interferon genes (STING) mediates inflammatory and antiviral cellular programmes by engaging the transcription factors interferon regulatory factor 3 (IRF3) and canonical NF-κB (RELA–p50). IRF3 activation is strictly controlled by TANK-binding kinase 1 (TBK1), which binds to the C-terminal tail (CTT) of STING through a conserved PLPLRT/SD binding motif to then phosphorylate Ser366 within the CTT (phospho-site). In certain cells, activation of NF-κB is less dependent on the CTT and TBK1. In addition, non-canonical NF-κB (RELB–p52) is activated downstream of STING and counteracts IRF3 and canonical NF-κB signalling. STING impacts cell survival and cellular proliferation in diverse ways and is associated with the induction of apoptosis, necroptosis, pyroptosis and cellular senescence. Both necroptosis and senescence can be triggered by STING-induced cytokines. Apoptosis induction can proceed through the upregulation of pro-apoptotic genes (PUMA, NOXA) or, alternatively, directly engage BAX and BAK at the mitochondrial membrane. STING-mediated lysosomal damage has been shown to activate NLRP3 inflammasome-dependent pyroptosis. b | Intercellular 2′,3′ cyclic GMP–AMP (cGAMP) transfer can be mediated by connexin proteins that form gap junctions between neighbouring cells, which can be homotypic or heterotypic. Additionally, various cell types use the voltage-dependent anion channel (VDAC) composed of LRCC8 subunits to import and export cGAMP. In the extracellular space, cGAMP is subject to degradation by the enzyme ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1). Tumour cells have also been shown to export cGAMP whereas myeloid cells use SLC19A1 or P2XR7 to import cGAMP. Connexin channels also mediate heterotypic cellular cGAMP transfer. APC, antigen-presenting cell; cGAS, cyclic GMP–AMP synthase; IFN, interferon; ISG, interferon-stimulated gene.
cGAS–STING and autophagy
The discussion so far has focused on STING-mediated control of gene transcription, but STING also promotes more immediate (antiviral) cellular processes, with autophagy being a key effector activity. Indeed, cGAS–STING signalling is intimately tied to autophagy — not only does cGAS–STING induce autophagy, as a cell-autonomous defence mechanism, but conversely it is also subject to regulation by autophagy components. Several earlier studies investigated the connection between STING and autophagy with some unresolved differences in the exact mechanism of autophagy induction, potentially reflecting a strong context-dependent regulatory component. Although canonical autophagy, relying on the ULK complex and TBK1, has been implicated in the control of STING-mediated autophagic vesicle formation, it appears that activation of STING can also trigger a non-canonical autophagy response requiring only selective autophagy machinery components, including the PI3P effector WIPI2 and the ATG5-12-16L1 complex. Befitting its critical role in cell autonomous antiviral immunity, autophagy induced by STING restricts viral propagation and could have served as a major host defence programme in certain species. For humans, the STING–autophagy connection appears to serve an additional benefit to the host. As such, a recent study reported that during replicative crisis, cells engage the STING–autophagy pathway to drive an autophagic cell death programme, thereby preventing tumour cell outgrowth. Of note, autophagy components also feed back on the regulation of STING activity by assisting STING intracellular trafficking capabilities as well as its lysosomal degradation. Accordingly, cells deficient in autophagy proteins or treated with drugs that inhibit lysosomal acidification, display enhanced type I interferon production. Interfering with autophagy pathway components in tumours augments the efficacy of antitumour strategies in a STING-dependent manner, consistent with heightened cGAS–STING pathway activity. Autophagy also prevents STING activation by delivering cytosolic DNA to the lysosome where it is degraded by DNase II. Altogether, autophagy is a key downstream activity of STING, which is not only important as a downstream effector module, but also as a critical coordinator to restore homeostasis after pathway engagement.

Anti-proliferative and cell death functions
Activation of STING initiates cascades that support anti-proliferative cell states, including cellular senescence, and ultimately cell death (a more detailed discussion of senescence is provided further below). To that end, STING promotes induction of cell-cycle inhibitors (such as p21) and pro-apoptotic BH3-only proteins. Alternatively, and in a more direct mode of action, phosphorylated IRF3 can also interact with the pro-apoptotic proteins BAX and BAK and thereby lead to transcription-independent induction of apoptosis downstream of STING. Under conditions in which apoptosis is inhibited, STING activation can also promote RIPK3-dependent necroptosis by engaging type I interferon and TNF signalling pathways. How cells balance these distinct outcomes of STING activation remains a question of ongoing research. But it appears that whether cells commit or not to death is context dependent and influenced by both the cell type and the specific cellular context (mitosis versus interphase). Both lymphocytes and monocytes appear to preferentially die following STING activation, a phenotype that is also observed in the context of hyperactive STING mutations in humans (see below). Given that cell death is a key initiator and amplifier of inflammatory conditions, it will be important to keep in mind these effector functions when considering the origins and/or consequences of STING-mediated inflammatory disease processes.

Intercellular cGAMP signalling networks
The finding that cGAS and STING connect through a transmittable second messenger molecule raised early on the idea that the pathway may also coordinate multicellular immune responses through the intercellular exchange of cGAMP. Indeed, although different modes of cell-extrinsic cGAMP signalling continue to be uncovered, we now recognize that cGAMP-induced immunity engages in substantial intercellular communication, greatly amplifying the overall immune response with important biological consequences.

The phenomenon of cGAMP in trans signalling was first shown to be mediated by gap junctions, intercellular conduits built of connexin proteins that directly connect the cytosol of adjacent cells. Following DNA transfection or virus infection of cells, cGAMP spreads from the producer cell to surrounding bystander cells causing prominent activation of STING and boosting antiviral immunity. Gap junctions not only form between identical cell types but are also established in more heterogeneous populations of cells that interact in the context of physiological immune responses. As such, gap junction-mediated cGAMP transfer has been found to amplify inflammatory responses in the setting of cancer, with cancer cells serving as the cGAMP producers and astrocytes or dendritic cells (DCs) as the cGAMP recipients. Depending on the context this can have either beneficial or maladaptive effects on tumour progression. In addition, interhepatic propagation of cGAMP was shown to fuel liver injury caused by alcohol. Evidently, this propagation mechanism is spatially restricted to layers of surrounding cells in the immediate vicinity. By contrast, vesicles, dying tumour cells and viruses have also been shown to serve carrier functions for cGAMP, which could bridge significantly longer distances. Both transmission modes have in common that they will avoid exposure of cGAMP to the extracellular space. This could be significant, as this is where cells express ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1), an ambiguous enzyme capable of degrading cGAMP and thus counteracting cGAMP-driven intercellular communications. However, more recent studies
describe a variety of non-specific transmembrane carriers capable of shuttling cGAMP and its derivatives across cellular membranes, including members of the solute carrier family and volume-gated anion channels.

For example, LRCC8 facilitates cellular entry of cGAMP, a function that if genetically ablated compromises defence against HSV-1 infection. In preclinical models of cancer, the transmembrane folate receptor SLC19A1-mediated cGAMP internalization is important for the efficacy of immunotherapies involving intratumoural administration of cGAMP.

Similarly, ATP-gated P2XR7-mediated cGAMP uptake promoted antitumour immunity. Operating on the basis of diffusion along physicochemical gradients, these dedicated importers may also invert their function and promote cGAMP export in certain scenarios. More generally, the activity of intercellular transport systems dramatically depends on cell type and activation state and, thus, their contribution to cGAMP-mediated immune responses may dramatically depend on the (local) cellular composition and the ‘activation’ state of the tissue. Future work will need to expand on their contributions to inflammatory disease states, which may shed light on intercellular amplificatory loops as new targets for aberrant cGAS–STING pathway activation.

**Sensing of cellular perturbation by cGAS–STING**

Instead of being activated by pathogen-specific structural patterns, cGAS–STING-mediated immunity in bacteria appears to have relied on an indirect means of danger sensing, that is, overcoming a constitutive, perhaps homeostatic, mechanism of self-inhibition. Although the acquisition of a DNA ligand-mediated mode of allosteric activation has allowed the cGAS–STING pathway to operate as a classical pattern recognition receptor, mammalian cells also benefit from danger sensing that is fuelled by cGAS-mediated recognition of out-of-context self-DNA. Similarly, several sterile disease states feature loss of cellular DNA homeostasis with distinct mechanistic scenarios of cGAS–STING pathway activation having been developed, as presented in detail below and highlighted in Fig. 3. Importantly, these different models of activation are not mutually exclusive, but instead may trigger cGAS activity in a redundant manner in certain cases and in a synergistic fashion in other cases.

**Activation by extracellular self-DNA sources**

Non-apoptotic cell death can lead to unprogrammed extracellular release of DNA, and several conditions associated with accrual of dying cells have been linked to activation of cGAS and/or STING. For example, irradiation of the tumour bed promotes internalization of tumour-cell-derived DNA in DCs, which elicits cGAS–STING activation. Likewise, synchronized cell death arising from acute ischaemic events, including occlusion of the coronary arteries, promotes the recruitment and activation of monocytes, an inflammatory event depending upon STING.

Adjuvant-mediated cell death has been shown to promote immune activation via STING. Additionally, neutrophil extracellular trap (NET) formation — a process implicated in various sterile inflammatory diseases — results in cell death and extrusion of neutrophil DNA–protein complexes into the extracellular space and in turn activates STING.

What these distinct mechanisms appear to have in common is that the dominant responding cell type is of myeloid origin, suggesting a correlation with the cellular capacity to engulf extracellular material. Whether internalized DNA simply overloads the homeostatic disposal mechanism or whether there are dedicated host factors involved in facilitating extracellular DNA recognition by cGAS remains unknown. What is known, however, is that impairment of the regulated turnover of apoptotic cell corpses can also trigger cGAS–STING activity. The best studied example of this is deficiency of DNase II, a lysosomal DNase crucial for the degradation of apoptotic-cell-derived DNA. Mechanistically, this phenotype has been associated with accumulation of dying erythrocytes in liver macrophages. More recent studies have illuminated further upstream factors that could play a role in the regulated degradation of DNA in apoptotic cells and prevention of cGAS activity. LC3-associated phagocytosis (LAP) is a non-canonical form of autophagy, which crucially functions in phagosome maturation and the regulation of downstream (immune) signalling events in macrophages and other cell types. It has been shown that deficiency of LAP components can promote STING activation within myeloid cells. The additional observation that TIM4 deficiency mimics this phenotype may suggest that dedicated apoptotic receptor pathways fuel extracellular DNA into an immunologically silent degradation process. However, if this route is overwhelmed and DNA internalization is mediated by other mechanisms, cGAS–STING activation may follow. Given that extracellular DNA is a major factor underlying many inflammatory phenotypes, a better understanding of the molecular routes taken by extracellular DNA will be of importance.

**Activation by cell-intrinsic mitochondrial DNA**

Release of mitochondrial (mt) DNA into the cytosol has emerged as a prominent trigger of cGAS–STING pathway activation in multiple contexts. Pathogens are well known to produce various signals capable of perturbing mitochondrial integrity, suggesting that the recognition of mtDNA via cGAS–STING could serve as an important means to signal the presence of infection. In support of this notion, antiviral immunity to HSV-1 and Dengue virus has been found to rely — at least to a certain degree — on cGAS recognition of mtDNA.

In addition, certain strains of *Mycobacterium tuberculosis* were found to drive cGAS activity via the release of mtDNA, although in this particular case the evoked type I interferon response may favour the pathogen rather than the host. Mitochondrial dysfunction and an accompanying rise in mtDNA levels can also accompany sterile inflammatory processes through the effects of cytokine signalling. For example, IL-1β, a hallmark inflammatory cytokine, and IFNα both compromise mitochondrial homeostasis and trigger an amplificatory immune reaction through the activity of mtDNA engaging cGAS. It is possible that, through such positive
regulatory mechanisms, diverse cytokine signalling programmes can cause potentiation of inflammation involving mtDNA recognition via cGAS. Defects in the clearance of damaged mitochondria due to mutations in PINK1 and Parkin, have also been linked to STING activity, implicating mitophagy as an important constitutive cellular process that limits aberrant immune activation91.

Similar to what is seen with genomic nuclear DNA, disruption of processes surrounding mtDNA intactness, replication and repair can result in cGAS–STING signalling. Among the best studied examples, is that defective
packaging of mtDNA into nucleoids following the depletion of transcription factor A mitochondrial (TFAM) is a prominent signal for cGAS activity in diverse cells. In addition, mtDNA stress invoked by lack of mitochondrial endonuclease G or by treatment with chemotherapeutic drugs activates cells via cGAS. In these and other instances, mtDNA may also be modified by mitochondrial reactive oxygen species that can render mtDNAs more resistant to processing by the nuclelease TREX1 and hence more stimulatory.

A most prominent cellular event of mitochondrial disintegration is apoptosis — a fundamental non-inflammatory mechanism of cell death. A compelling case has been made in support of an essential function of apoptotic caspases to impair cGAS sensing of mtDNA and, hence, maintain the immunologically silent mechanism of apoptotic cell demise. How exactly caspases exert this anti-inflammatory function is not fully elucidated, but one potential strategy involves the regulated cleavage of cGAS and its downstream transcription factor IRF3 (REF. 78).

Compared with the importance to mtDNA-mediated activation of cGAS the mechanisms allowing mtDNA to translocate into the cytosol have only more recently been developed. To reach the cytosol, mtDNA must overcome two barriers — the inner mitochondrial membrane (IMM) and the outer mitochondrial membrane (OMM). In the context of apoptosis, BAX/BAK macro pores located in the OMM have been shown to serve as gateways for mtDNA herniating through inner nuclear membrane (INM) ruptures and, in turn, its escape into the cytosol. Importantly, beyond apoptosis, which is characterized by synchronized and complete mitochondrial outer membrane permeabilization (MOMP), cells may also experience more limited forms of MOMP affecting only a minority of mitochondria. Such minor MOMP could provide one explanation of how MOMP could connect with the cGAS–STING pathway in the context of more subtle (mitochondrial) stress responses. In addition, the oligomerization of the voltage-dependent anion channel proteins VDAC1 and VDAC3 leads to the formation of pores in the OMM that also allow mtDNA fragments to reach the cytosol. How the IMM permeabilizes is not yet fully understood, but it may involve the mitochondrial permeability transition pore (MPTP), which spans the IMM and forms as a consequence of diverse cellular stresses.

**Activation by cell-intrinsic genomic DNA**

Molecularly distinct disease-associated processes have been identified that underlie the cell-intrinsic activation of the cGAS–STING pathway by genomic DNA. As of today, most of these processes are characterized by the accumulation of nuclear DNA inside the cytoplasm providing a straightforward mechanism of cGAS activation by out-of-context DNA. However, the localization of cGAS within the nucleus raises the possibility that under conditions of disease, aberrant cGAS activity may also arise directly from sensing genomic DNA inside the nucleus (Box 1).

Early studies recognized that the cytosolic enrichment of retrotransposable elements serves as a potent trigger of type I interferon responses. One could well argue that the sensing of retroelements may in fact represent a primary function of cGAS in the context of retrovirus infection. Retrotransposon sequences occupy a considerable fraction of the human genome, but most of these sequences are severely truncated and, thus, considered non-functional. Whereas so-called LINE-1 (L1) elements can still undergo retrotransposition, various actions counteract the propagation of L1 elements in living cells under homeostatic conditions. However, imbalances in the surveillance strategies for endogenous retroelements can trigger cGAS activity, owing to improper accumulation of cDNA intermediates. The best studied example of the ability to directly recognize overt retrotransposon activity by cGAS is loss of the repair exonuclease TREX1, which naturally antagonizes this process by cleavage of DNA intermediates. Deficiency of TREX1 causes accumulation of L1 elements in mouse tissue and human neural stem cells. Further upstream derepression of retroelements via epigenetic alterations occurs naturally during ageing and this gives rise to cytoplasmic L1 and cGAS–STING-dependent inflammation. Given that retro-transcription of L1 elements is believed to occur within the nucleus it remains to be fully elucidated how exactly these cDNA intermediates are exported to the cytosol.

Another obvious category of cell-intrinsic stimulatory DNA products are those emerging from DNA damage and defective replication and repair. Mutations in or deletion of a range of genes that control these processes have served as important experimental paradigms that link DNA damage with activation of cGAS–STING signalling. Likewise, various exogenous genotoxic treatments have been linked to a cell-intrinsic cGAS-dependent type I interferon response.

**Box 1 | Mechanisms of cGAS inhibition inside the nucleus**

Compartmentalization of genomic DNA in the nucleus has long been perceived as a critical mechanism protecting genomic DNA from cyclic GMP–AMP synthase (cGAS) detection and auto-reactivity. However, a fraction of cGAS is present in the nucleus at steady state implying the existence of potent inhibitory mechanisms that restrict its catalytic activity on chromatin. Recent studies have unfolded molecular mechanisms that — in a manner distinct from purely physical separation — allow rapid silencing of cGAS on intact chromatized DNA by focusing on restricting DNA accessibility or inhibitory engagement with the nucleosome. First, through its capacity to bind to DNA in a universal manner, barrier-to-autointegration factor (BAF) prevents cGAS activity by dynamically displacing it from genomic DNA. This safeguard is relevant both upon transient exposure of chromatin during acute nuclear rupture events and, moreover, following enhanced nuclear cGAS localization. Second, cGAS undergoes strong inhibitory association with nucleosomes, which were found to suppress cGAS catalytic activity. Structural studies have shown that engagement with the nucleosome is largely achieved through a bipartite interface that mediates cGAS interaction with the acidic patch of the nucleosome surface formed by the H2A–H2B dimer on the one hand and with nucleosome DNA on the other hand. Notably, mutations within LSM11 and RNUF-1, which are genes that regulate de novo histone transcription, were found in patients with an Aicardi–Goutières syndrome phenotype. It was found that defects within these genes perturb linker histone H1 expression, which can trigger abnormalities of cGAS localization and cGAS- and stimulator of interferon genes (STING)-dependent type I interferon production. Together, this suggests a dynamic and context-dependent relationship between distinct mechanisms — competition for DNA binding, limiting unrestricted access and inhibition by the nucleosome core particle and linker histones — that were evidently necessary to achieve a proper level of regulation of cGAS on chromatin inside the nucleus.
Importantly, however, there are profound differences with regard to the mechanisms of DNA accrual and subsequent cGAS engagement. First, under certain conditions, free DNA-damage products have been reported to reach the cytosol directly, although how these products traverse the nuclear membrane remains to be resolved. Alternatively, unrepaired or profoundly damaged genomic DNA promotes chromosome missegregation and micronuclei formation or the generation of chromatim bridges in mitosis. Upon rupture, cytosolic cGAS gains access to the damaged chromatin inside micronuclei leading to immune activation in several contexts of genome instability. Alternatively, enveloped chromatin fragments can also bud off the main nucleus in senescent cells, an event that is believed to be due to increased fragility of the nuclear lamina.

**Activation of cGAS–STING in disease contexts**

The remarkable complexity that is inherent in the proper regulation of DNA abundance, sequestration and clearance at both the cellular and organismal level makes it vulnerable to perturbations. Although the inducers of pathological processes are disease-specific, there is evidence for considerable convergence on the involvement of the cGAS–STING pathway as a driver of both (hyper-)acute and chronic, low-grade inflammatory conditions associated with diverse pathologies. Owing to its central role as a ubiquitous and sensitive mechanism of out-of-context DNA recognition, this may not be too surprising. In addition, first evidence indicates that imbalances in intracellular trafficking routes can have profound repercussions on STING activity and contribute to improper immune activation. Below we highlight implications of the cGAS–STING pathway in distinct disease processes and provide a summary of the additional literature surrounding this aspect in **TABLE 1**.

**Implications of cGAS–STING in monogenic diseases**

Rare monogenic autoinflammatory diseases are associated with mutations in genes that participate in innate immunity or that control innate immune homeostasis. Here, we briefly highlight a selection of conditions as they relate to a cGAS–STING-driven pathogenesis implying the opportunity for interventions predicated on the inhibition of cGAS and STING. For more comprehensive reviews on type I interferonopathies, particularly characterized by early onset of progressive encephalopathy and skin lesions (referred to as chilblains), with the development of other features being intentionally characterized by early onset of progressive encephalopathy and skin lesions (referred to as chilblains), with the development of other features being reportedly existing between individual patients. Mutations in a subset of these genes — namely, TREX1, genes encoding the three RNase H2 endonuclease subunits, RNASEH2A, RNASEH2C, and SAMHD1 — have been associated with disturbed self-DNA metabolism and constitutive activation of the cGAS–STING pathway. As such, mice deficient for or with mutation in AGS-associated genes have been developed, and data derived from these animals have shown that co-depletion of cGAS or STING reverses the pathogenesis seen in mice. More recently, a clinical syndrome with an elevated type I interferon signature was found to be caused by hypomorphic mutations in DNAse2 (REF. As distinct from AGS, the disease manifested with neonatal anaemia, kidney disease and arthropathy. Dnase2−/− mice die during embryonic development owing to severe anaemia and if crossed with Ifnar null mice, develop an arthritis phenotype. In that sense, the mouse models, although more severe, overlap with the features seen in patients. Notably, depletion of either cGAS or STING protects Dnase2−/− mice from developing disease. It is important to keep in mind the existence of considerable differences in the phenotypic consequences between these preclinical models and patients with mutations in DNA metabolism.
with regard to the overall disease severity, the variability of developing disease and the involvement of given organ systems, especially with regard to the neurological phenotype, which is absent in mouse models. Still, these genetic disease models unequivocally support the view that cGAS–STING signalling drives autoinflammatory disease features and that drugs blocking cGAS or STING could be used to treat these conditions.

**Table 1** | **Associations of the cGAS–STING pathway with inflammatory diseases**

| Type of disease or condition | Specific disease | Link to cGAS–STING pathway | Refs |
|-----------------------------|-----------------|----------------------------|------|
| **Monogenic autoinflammatory syndromes** | STING-associated vasculopathy with onset in infancy (SAVI) | Disease caused by GOF mutations in STING1 | 113,114 |
| | Aicardi–Goutières syndrome (AGS) | Disease associated with perturbation of nucleic acid metabolism. Pathology due to defects in a subset of AGS genes is rescued in cGAS-deficient or STING-deficient mice | 115–117, 182–194 |
| | Familial chilblain lupus | Disease can be caused by STING1 GOF mutation | 195 |
| | COPA syndrome | Pathology reduced in STING-deficient mice or mice treated with a STING inhibitor and in patient cells upon STING suppression | 37,38, 133,134 |
| **Autoimmune diseases** | Systemic lupus erythematosus | Subset of patients have elevated cGAMP levels. Pathology of certain mouse models, which display a lupus-like phenotype, can be rescued in STING-deficient mice | 115,116,140 |
| | Rheumatoid arthritis | Reduced cytokine expression in patient cells following cGAS or STING knockdown | 196 |
| **Neurological disorders** | Ischaemic brain injury | Pathology reduced in mouse models treated with inhibitory oligonucleotide A151 | 197 |
| | Parkinson disease | Pathology reduced in STING-deficient mouse models | 91 |
| | General neurodegeneration | Reduced inflammation markers seen in a STING-deficient mouse model | 149 |
| | Huntington disease | Cytokine expression within patient cells reduced upon cGAS depletion | 147 |
| | Amyotrophic lateral sclerosis and frontotemporal dementia | Protection in STING-deficient mice or in mice treated with a STING inhibitor. Reduced type I interferon expression in patient cells treated with a STING or cGAS inhibitor | 101,145 |
| | Age-dependent macular degeneration | Protection in cGAS-deficient and STING-deficient mice models | 198 |
| | Traumatic brain injury | Reduced neuroinflammation seen in STING-deficient mice | 207 |
| **Metabolic diseases** | Nonalcoholic steatohepatitis | Protection seen in STING-deficient mice | 199 |
| | Alcoholic liver disease | Protection in STING-deficient mice | 60 |
| | Acute pancreatitis | Protection seen in cGAS- or STING-deficient mouse models | 200 |
| **Inflammatory diseases** | Silica-induced fibrosis | Pathology reduced in STING-deficient mice | 201 |
| | Sepsis | Protection seen in STING-deficient mice | 202,203 |
| **Cardiovascular diseases** | Myocardial infarction | Protection in cGAS-deficient or STING-deficient mice | 81,204 |
| | Chronic heart failure | Protection when cGAS is inhibited (via an AAV vector) | 205 |
| **Cancer** | Colorectal cancer | Protection in STING-deficient mouse model | 206 |
| | Skin cancer | Protection in STING-deficient mice | 149 |
| | Metastases | Protection seen with STING-deficient tumour cells | 51 |
| **Senescence and ageing** | Senescence | Protection against senescence seen in cGAS-deficient or STING-deficient cells or mice | 58,155,156 |
| | Ageing | Ageing-associated inflammation reduced in STING-deficient cells | 103,157 |

AAV, adeno-associated virus; cGAMP, 2′-3′ cyclic GMP–AMP; cGAS, cyclic GMP–AMP synthase; GOF, gain of function; STING, stimulator of interferon genes.

**COPA syndrome.** COPI is critical for the retrieval of proteins from the Golgi to the ER and for intra-Golgi transport. COPA syndrome is a rare early-onset autosomal
dominant disease caused by missense mutations in the COPA gene, which encodes the COPα protein subunit of the COPI complex; the mutation impairs the binding and sorting of proteins targeted for ER retrieval134. Clinically, patients typically present with inflammatory arthritis, interstitial lung disease and kidney disease and exhibit a type I interferon signature in blood — features that are to some degree reminiscent of SAV132. Recently, four independent studies have shown that defects caused by COPA mutations promote ligand-independent activation of STING-mediated signalling and that the elevated type I interferon signature associated with COPA dysfunction can be reduced by genetic or pharmacological interference with STING133,134. In a mouse model of COPA syndrome (Copa E241K/+) type I interferon-driven inflammation was rescued by crossing these mice with STING-deficient (STING−/−) animals and, moreover, the embryonic lethality of homozygous Copa E241K/E241K mice was rescued by co-deletion of STING135. Together, these studies suggest that STING may play an important role in the excessive inflammatory phenotype in COPA syndrome.

cGAS–STING in SLE and other autoimmune diseases

With both type I interferons and self-nucleic acids recognized as hallmark drivers in the pathogenesis of systemic autoimmune diseases, the involvement of the cGAS–STING pathway in these diseases is of great interest. For systemic lupus erythematosus (SLE), the prototypic chronic systemic autoimmune disease, it has been documented that ~15% of a total cohort of 41 patients displayed elevated levels of cGAMP in the serum — a strong indicator of the presence of cGAS pathway activity136. Moreover, serum collected from patients with SLE was shown to amplify type I interferon induction via STING, providing a mechanism for how cGAS–STING may amplify or accelerate disease symptoms137. Mutations of TREX1 can cause monogenic forms of cutaneous lupus, and TREX1 variants have been reported in a large cohort of patients with SLE, although these occur in only a minor fraction of patients138,139. Judging from animal models, the relevance of cGAS–STING signalling in the pathogenesis of SLE is variable and considerably dependent on the mouse model under study. Given the multitude of pathological mechanisms underlying SLE, this is not unexpected and rather reflects the considerable heterogeneity of SLE in humans. Early work found that the genetic deletion of STING in the lupus-prone MRL-Fas80 mice aggravated the disease phenotype140. By contrast, in another model driven by a deletion in the lupus susceptibility gene Fcgr2b, Sting1 null mice were protected from development of various disease manifestations, including elevated autoantibody titres and glomerulonephritis, and showed improved overall survival140. Moreover, cGAS–STING plays a pathogenic role in a variety of distinct models that promote lupus-like symptoms through a range of mechanisms. As such, defects in extracellular clearance of apoptotic cells, accumulation of extracellular NETs from dying neutrophils, defects in mtDNA replication and dysregulation of endogenous retroelements have been suggested to predispose to the development of cardinal disease features of SLE and present plausible mechanisms of aberrant cGAS activity in SLE141–143.

Implications of cGAS–STING in neurodegeneration

Inflammation is a prominent hallmark of several neurodegenerative diseases, including Alzheimer disease, Parkinson disease and amyotrophic lateral sclerosis (ALS)144. Multiple recent studies associate activation of the cGAS–STING pathway with the development of some of these neurodegenerative pathologies. As a most illustrative example, a mechanism that connects compromised mitophagy to activation of cGAS–STING signalling has recently been identified that may be relevant to the pathology of Parkinson disease145. Parkinson disease is a debilitating movement disorder resulting from selective death of dopamine-producing neurons in the substantia nigra region of the midbrain. Missense mutations in PARKIN and PINK1, which encode proteins that assist in the removal of dysfunctional mitochondria, are linked to familiar forms of Parkinson disease. In the context of in vivo mitochondrial stress, it was found that mice deficient in either Parkin or PINK1 accumulate mtDNA and display elevated cytokine levels in the bloodstream, the latter effect being fully abrogated by co-deletion of STING145. Importantly, absence of STING also rescued the motor deficit and neuronal cell loss seen in aged Parkin mutant mice, which develop neuronal abnormalities similar to those in patients with Parkinson disease146. More recently, cGAS–STING-dependent inflammatory processes driven through the recognition of mtDNA have been found to trigger neuropathological processes associated with certain forms of ALS and frontotemporal lobar degeneration (FTLD)147. Cytosolic and mitochondrial accumulation of TDP43, a DNA/RNA-binding protein normally sequestered in the nucleus, is a hallmark of many cases of ALS and FTLD. Mislocalized mitochondrial TDP43 causes mtDNA release through the opening of the MPTP and leakage via VDAC1 followed by the induction of type I interferons and inflammatory cytokines in a cGAS–STING-dependent fashion in human and mouse cells. Moreover, motorneurons derived from patients with ALS showed STING-dependent upregulation of inflammatory cytokines. In a preclinical model of ALS driven by overexpression of TDP43, co-deletion of STING dampened neuroinflammation, mitigated rapid disease progression and protected from early death. Strikingly, attenuation of signs of neurodegeneration was also observed upon deletion of only one allele of STING or by the application of a pharmacological inhibitor of STING. A link between inflammation associated with ALS and cGAS–STING activity also came from another recent report that investigated the biological consequences of diminished C9orf72 levels — mutations of which are the most common genetic causes of ALS and FTLD. Myeloid cells deficient for C9orf72 as well as cells from patients with C9-ALS/FTLD showed STING-mediated production of type I interferons and inflammatory mediators148. Mechanistically, compromised C9orf72 expression was suggested to hamper the swift degradation of STING, consistent with a function of C9orf72 in the regulation of lysosomal...
vesicle formation. Lastly, elevated levels of type I interferons and contributions of STING have also been observed in models and disease samples of Huntington disease or neurodegeneration due to extracellular protein aggregate formation. Future work will be needed to further dissect the cell types involved in cGAS–STING-driven inflammation and to assess whether interfering with the cGAS–STING signalling axis may merely stop and slow down or, perhaps, even reverse molecular changes associated with neurological deterioration. In summary, these studies imply that despite occurring secondary to initial degenerative changes in the brain, aberrant activation of the cGAS–STING pathway is relevant in distinct types of neurodegeneration, and inhibiting cGAS or STING may improve certain disease states or mitigate disease progression.

**Implications of protumorigenic roles of cGAS–STING**

Owing to its potent immune-stimulatory effects, the cGAS–STING pathway holds particular translational appeal as a promising target for cancer immunotherapy. However, in striking contrast to their tumour suppressive roles, cGAS and STING have also been implicated in promoting tumour burden and worse disease outcomes in models of cancer. This raises the question of what dictates these fundamentally distinct outcomes of cGAS–STING activity in tumours? Valuable clues to answering this question came from studying the kinetics and strength of cGAS–STING activation. As such, whilst transient activation appears favourable, adverse effects seem to rely on the stimulation of a chronic inflammatory programme that promotes an immune-suppressive tumour environment. For example, chronic exposure to genotoxic 7,12-dimethylbenz(a)anthracene (DMBA) promotes tumour growth in a STING-dependent manner. Similarly, STING-mediated recruitment of myeloid-derived suppressor cells promotes MC38 colon cancer growth following radiation therapy. STING ligands can also induce the expression of inhibitory molecules, for example, PDL1 or IDO1, or activate non-canonical NF-κB signalling, which counteracts the tumour-suppressive effects of type I interferons. The pro-apoptotic effects of STING on T cells may also contribute to limited tumour cell clearance. Beyond shaping the immune cell composition at the primary tumour site, the cGAS–STING pathway also impacts metastatic behaviours. Indeed, by activation of STING signalling, chromosomally unstable tumours upregulate genes relevant for epithelial–mesenchymal transition and metastasis through non-canonical NF-κB signalling. Moreover, on reaching unaffected distant sites, such as the brain, metastatic breast cancer cells also utilize cGAMP transfer to manipulate immune cells for their own growth advantage. Although these pro-tumorigenic effects are reliant on cGAS–STING signalling, a recent report implies that nuclear cGAS can directly promote uncontrolled cancer cell proliferation independently of STING by inhibiting homologous recombination. All in all, these aspects suggest a complex role of the cGAS–STING pathway in cancer. In the context of more advanced disease, a STING-mediated inflammatory retrenchment may allow aggressive cancer cells to adapt, and overcome and finally to further thrive and propagate — highlighting that chronic STING signalling may represent a key problem that must be taken into consideration for tumour therapies targeting this pathway.

**cGAS–STING in senescence and ageing**

During ageing crucial mechanisms that maintain tissue and cellular homeostasis collapse, generating the accumulation of a plethora of molecules that can fuel the heightened inflammatory state characteristic of old age in various species, including humans. Crucial to this ‘inflammageing’ process are senescent cells, which amongst other features have lost the capacity to proliferate and display prominent secretory activity, referred to as the senescence-associated secretory phenotype (SASP), which can impair tissue function. Depletion of senescent cells prolongs lifespan and healthspan and ameliorates several ageing-associated dysfunctions. Furthermore, transplantation of senescent cells into young mice accelerates the establishment of several ageing-associated frailty aspects, underscoring the critical role of senescent cells in regulating features of ageing.

We, and other groups, have discovered that aberrant activity of cGAS–STING is a conserved pattern across multiple types of senescent cells and that this is critical for the secretion of several SASP components. Mechanistically, cGAS was found to be enriched on cytosolic chromatin that can accumulate within senescent cells and represent a bona fide activator for cGAS in this context (see above). As potential sources, cytosolic DNA fragments may derive from ruptured micronuclei or chromatin herniations, as a consequence of chronic DNA damage of disrupted nuclear envelope integrity, both of which are features of senescent cells. Alternatively, a recent report proposed accumulation of cytosolic retrotransposable elements, which can become reactivated during ageing in somatic tissues, to drive cGAS-dependent type I interferon responses. Strikingly, repressing retrotransposon transcription using the nucleoside reverse transcriptase inhibitor lamivudine dampens signs of inflammageing in multiple tissues in naturally aged mice and in a prorogeroid model of ageing. Given that senescent cells have gained broader attention in other disease settings, such as osteoarthritis and artherosclerosis, further studies into the connection between inflammatory senescence and cGAS–STING are warranted. Age-associated decline in mitochondrial function is also a hallmark of ageing. Interestingly, depletion of TFAM — a well-known trigger of cGAS–STING activity in multiple settings — in T cells is sufficient to trigger an accelerated ageing phenotype and multimorbidity by promoting a pro-senescent inflammatory milieu in vivo. In light of these advances, it is tempting to speculate that aberrant cGAS–STING signalling may contribute to functional decline and ageing-related dysfunction imparted by its pro-inflammatory properties.

**Therapeutic targeting of cGAS–STING**

The findings discussed above on the involvement of cGAS–STING in a number of pathologies with so far unsatisfactory or unmet therapeutic options portend its high potential as a drug target. The emergence of...
first drug-like compounds selectively targeting cGAS or STING has opened the door for the development of first clinical candidates. Here, we discuss emerging small-molecule-based strategies to therapeutically target cGAS–STING signalling in models of disease. The chemical structures of specific agents targeting cGAS and STING are summarized in Table 2 and Table 3, respectively. An overview of their mechanisms of action is provided in Fig. 4. Considerations on human STING allelic variants are presented in Box 2.

**cGAS inhibitors**

Given the amenability of cGAS to crystallography, a number of reports have detailed the structure-based design of cGAS inhibitors. Most of the cGAS antagonists discovered in this manner bind to the active site and are thus competitive with the ATP or GTP substrates or the product cGAMP. The other main class of cGAS antagonists described in the literature compete with DNA for binding to cGAS, thus interfering with the initial activation step of cGAS. A brief summary of these cGAS inhibitors is presented in the following section.

** Catalytic site inhibitors**

*PF-06928125.* Hall et al. conducted a saturation transfer difference 1H NMR screen of the Pfizer fragment library against a truncated cGAS construct. In concert with surface plasmon resonance (SPR) and fluorescence polarization (FP) assays, they identified a tetrazolo[1,5-a]pyrimidine fragment with a $K_{i}$ of 171 µM (SPR). X-ray crystallography (3.1 Å resolution structure) confirmed that this compound binds to the active site of cGAS at a region typically occupied by the adenosine base of ATP or cGAMP. Using this information and together with other published crystal structures, the team modified the core and created additional interactions within the active site to identify pyrazolopyrimidine PF-06928125, with a $K_{i}$ of 0.2 µM by SPR and $K_{i}$ of 4.9 µM in the FP assay. Although this compound was shown to bind to cGAS in biochemical assays, PF-06928125 lacked inhibitory activity in cellular assays. The authors speculated that inhibiting the active site might require more potent compounds, owing to high intracellular levels of ATP and GTP. In addition, they proposed that additional changes to the core to replace the carboxylic acid with a motif that would have a higher $pK_a$ lower polar surface area and fewer H-bonds could improve resultant cellular potency.

*RU.521.* Vincent et al. conducted a high-throughput screen using recombinant mouse cGAS (m-cGAS) and a RapidFire mass spectrometry system (RF-MS) to quantify levels of ATP, GTP and cGAMP as readout. Screening 123,306 compounds led to the identification of four compounds that survived both in silico filters for PAINS motifs and counter-screening to remove DNA intercalators. A 2.13 Å resolution crystal structure of one of these hits (RU.365) bound to cGAS with dsDNA confirmed that the compound occupied the active site of cGAS. Subsequent structure-guided chemical synthesis of analogues led to the identification of RU.521, with a $K_{i}$ of 36 nM as assessed by isothermal titration calorimetry. This compound was also the most potent compound of this series in a cellular assay ($IC_{50} = 0.70$ µM) that measured the inhibition of dsDNA-induced cGAS signalling in RAW macrophage cells. The inhibitory effect of RU.521 was selective for cGAS versus other innate immune signalling pathways and was shown to reduce expression levels of Ifnb1 mRNA in bone marrow-derived macrophages (BMDMs) from *Trex1*−/− mice, demonstrating the potential for this compound to be effective in a constitutively activated system.

*G150.* Lama et al. recently reported the identification of a new class of active site-targeted inhibitors of cGAS. In this communication, the group used a new luminescence-based assay system that allowed them to screen h-cGAS. This screening campaign of 281,348 compounds was triaged in a manner similar to that used to identify RU.521. This screen identified two main chemotypes (J and G), of which chemotype G, with a pyridoindole tricyclic core, was used as a starting point to ultimately derive G150 (RF-MS $IC_{50} = 0.0102$ µM for h-cGAS). Using an *IFNB1* mRNA readout, G150 had an $IC_{50}$ of 1.96 µM in THP-1 cells and an $IC_{50}$ of 0.62 µM in primary human macrophages. G150 also showed no off-target effects in a series of assays testing inhibition of other innate immune sensing pathways. The X-ray structures of G150 and a number of other analogues confirmed their binding of the cGAS active site. However, the authors note that they have not been able to rationalize all of the structure–activity relationships (SARs) based on this information, and more work will be needed to design and develop next-generation inhibitors.

*Compound S3.* Zhao et al. solved a 1.8 Å resolution crystal structure of a h-cGAS structure bound to PF-06928125, which they then used to conduct a virtual screen of about 1.5 million compounds in the ChemDiv database. Following up on 59 compounds for biological testing in thermal shift assay provided four positive hits. Co-crystal structures of these hits revealed that they bound the active site of cGAS in a manner that correlated well with their docking models from the virtual screen. However, subsequent assessment of the compounds in a PPase-coupled assay measuring cGAS catalytic activity revealed that they did not inhibit cGAS enzymatic activity. Instead, while screening the initial virtual screen hits in the PPase-coupled assay, they found that one of the original 59 hits had an $IC_{50}$ of 29.9 µM even though it did not have any activity in the thermal shift assay. An expanded similarity search around this compound, combined with docking assessment, identified 21 new compounds for purchase. From this endeavour, they identified compound S3, with an $IC_{50}$ of 4.9 µM in the PPase-coupled assay (for comparison, PF-06928125 has an $IC_{50}$ of 2.1 µM and RU.521 has an $IC_{50}$ of 5.7 µM in this assay). The authors compared the binding modes of compound S3 with those of PF-06928125 and RU.521 and recommended the virtual screening approach as a complementary method to identify new starting points for cGAS inhibitors.
| Compound  | Structure | Ref. |
|-----------|-----------|------|
| PF-06928215 | ![Structure](image1.png) | 160 |
| RU.365    | ![Structure](image2.png) | 12  |
| RU.521    | ![Structure](image3.png) | 12  |
| G150      | ![Structure](image4.png) | 161 |
| Compound S3 | ![Structure](image5.png) | 163 |
| Hydroxychloroquine | ![Structure](image6.png) | 164 |
| Quinacrine | ![Structure](image7.png) | 164 |
| X6        | ![Structure](image8.png) | 166 |
Inhibitors that disrupt DNA binding

Antimalarial drugs. Although inhibition of the active site of cGAS is an approach many research groups have pursued, another strategy would be to disrupt the binding of cGAS to dsDNA, which is the activating trigger for cGAS. An et al.\textsuperscript{164,165} reported that a series of antimalarial drugs, such as hydroxychloroquine and quinacrine, could be used as potential treatments for SLE and that these drugs inhibited IFNβ production by selectively blocking the cGAS–dsDNA interaction. They went on to describe the development of a second-generation molecule X6, with improved in vitro and in vivo activity\textsuperscript{166}. It has been shown that these classes of molecule can interact with DNA by both intercalation and association of the positively charged amino side chain within the minor groove of DNA\textsuperscript{169}. As such, the authors and others\textsuperscript{168} postulated that these molecules inhibit cGAS indirectly by binding to dsDNA and preventing the formation of the cGAS–dsDNA complex.

Suramin. Wang et al.\textsuperscript{168} screened a small 268-compound library and identified suramin as an inhibitor of cGAS activity. A series of experiments revealed that suramin likely inhibits cGAS activity by binding at the dsDNA-binding site, thus disrupting the formation of the cGAS–dsDNA complex. The authors also reported that the observed inhibition of cGAS is selective, with no effect on the TLR1/TLR2 or TLR4 pathways. Although the molecule is highly charged, suramin has been shown to have cellular activity. One potential mechanism of action suggested in this publication is that the anionic sulfates of suramin act as phosphate mimics and bind to the positive regions on cGAS.

Suppressive oligodeoxynucleotides. A151 is a suppressive oligodeoxynucleotide containing four TTAGGG motif repeats (5′-tt agg gtg agg ggg tgg agg g-3′). Initial reports described its inhibitory effects on both TLR9 signalling\textsuperscript{279} and AIM2 [Ref.\textsuperscript{31}]. In a recent report, Steinhagen et al.\textsuperscript{167} demonstrated that A151 can also function as a competitive inhibitor of cGAS by interacting with the dsDNA-binding domain. The exact binding sites of A151 within the DNA-binding domain are not known, but the authors did determine that binding is both sequence- and backbone-specific. In this study, A151 was also able to inhibit a type I interferon response in TREX1-deficient cells, raising the possibility of this approach to treat dsDNA-driven autoimmune diseases.

Compounds with undetermined mechanism of action

Padilla-Salinas et al.\textsuperscript{162} also used the Hall et al. crystal structure as a starting point to conduct a virtual screen. In particular, they targeted a potential druggable pocket around Lys347 and Lys394 in h-cGAS (Lys335/Lys382 in m-cGAS) near the dsDNA interface, with the aim of developing a protein–protein interface inhibitor of the cGAS dimer itself. They conducted a virtual screen of both the Maybridge (53,000 compounds) and Enamine (1.7 million compounds) collections, using reported co-crystal structures of m-cGAS to identify 10 compounds that met their screening criteria. Only one compound from this effort inhibited h-cGAS (1,3,5-triazine Z918) with an IC\textsubscript{50} of 100 µM in a KinaseGlo cGAS in vitro assay. They initiated a dedicated synthetic effort about this core and, through a series of optimizations, identified CU-76 as a potent cGAS inhibitor (IC\textsubscript{50} = 0.24 µM). The compounds were determined to be selective for cGAS versus other pathways, using a suite of assays similar to those described in the RU.251 and G150 work. The authors were not able to obtain a crystal structure of CU-76 bound to cGAS, although they did confirm that it does not disrupt formation of the cGAS–dsDNA complex, as originally hypothesized. As such, it is not known whether CU-76 binds to the active site or inhibits cGAS via another mechanism.

STING inhibitors

To date, two main approaches have been reported in the literature to identify STING inhibitors. The first is...
| Compound          | Structure | Ref. |
|-------------------|-----------|------|
| Screening hit Compound 1 | ![Structure](image1) | 172 |
| Compound 18       | ![Structure](image2) | 172 |
| Astin C           | ![Structure](image3) | 173 |
| C-176             | ![Structure](image4) | 13  |
| C-178             | ![Structure](image5) | 13  |
| C-170             | ![Structure](image6) | 13  |
| C-171             | ![Structure](image7) | 13  |
| H-151             | ![Structure](image8) | 13  |
| NO₂-cLA           | ![Structure](image9) | 174 |
| NO₂-OA            | ![Structure](image10) | 174 |
to design molecules that occupy the cyclic dinucleotide (CDN)-binding site, thus acting as competitive antagonists of STING activators. The second approach has been to identify inhibitors that bind to either the Cys88 or the Cys91 residue near the transmembrane domain of the STING protein, each of which is subject to palmitoylation. We briefly describe these approaches and representative STING inhibitors in the following sections.

**STING antagonists targeting the CDN-binding site**

*Tetrahydroisoquinolines.* Biophysical and X-ray crystallographic data show that the STING C-terminal domain exists as a symmetrical dimer, with the ligand-binding site located at the interface between the two monomers. Siu et al.\(^{172}\) took advantage of the symmetrical nature of the CDN-binding domain to design small-molecule antagonists that bind two identical molecules in the larger CDN-binding site. Using a mass spectrometry-based ligand screening technique, they identified a low-affinity hit (compound 1, HAQ STING IC\(_{50}\) = 7.5 μM). X-ray structure determination demonstrated that two molecules occupied the CDN site and that STING adopted the inactive, open conformation. This group identified several key polar and hydrophobic contacts, both between the two molecules occupying the binding site, and the protein itself. SAR studies probing these contacts, including modification of the pK\(_a\) of the acid, led to identification of compound 18 (HAQ STING IC\(_{50}\) = 0.08 μM). This molecule bound to STING in a similar manner (two molecules per STING dimer) and inhibited cGAMP-induced IFNβ secretion with an IC\(_{50}\) of 11 μM in THP-1 cells.

*Astin C.* Li et al.\(^{173}\) identified the natural product astin C from a reporter gene-based screen of a cyclopeptide library. Pull-down experiments using biotinylated astin C and human STING demonstrated that astin C binds competitively to the CDN site. In addition, adding an excess of unlabelled free astin C (10-fold) abolished the binding of biotinylated astin C to STING. Additional mechanistic studies revealed that astin C blocks the recruitment of IRF3 to the STING signalosome, thus preventing downstream signalling through the pathway. In vitro, astin C inhibited the expression of type I interferon in Trex1\(^{-/-}\) BMDMs. The investigators also explored the in vivo activity of astin C, administered as a C-HP-β-CD inclusion complex to Trex1\(^{-/-}\) mice, where it strongly inhibited the expression of Ifnb, Cxcl10, Isg15, Isg56 and Tnf mRNA in the heart, muscle, stomach and tongue of the mice, thus demonstrating in vivo modulation of STING.

**Targeting STING palmitoylation sites**

*Nitrofurans (C-176 and C-178).* We identified a series of nitrofuran derivatives from a cell-based screening campaign (HEK293T cells expressing murine STING)\(^{13}\). Using protein mass spectroscopy and an alanine scan we demonstrated that these inhibitors specifically and irreversibly bind to Cys91 of STING, but not the nearby Cys88, both of which are palmitoylated after CDN-stimulated activation. Using an azide-based clickable C-176 probe (C-176-AZ) and a gel-based protein profiling approach, we showed that C-176 was very selective for STING against a panel of proteins that contain hyper-reactive cysteine residues. Furthermore, pre-treatment of mice with C-176 markedly reduced STING agonist-mediated elevation of serum levels of type I interferons and IL-6. In addition, treatment of Trex1\(^{-/-}\) mice with C-176 resulted in a significant reduction in serum levels of type I interferons and in strong suppression of inflammatory parameters in the heart. A small set of analogues designed around C-176 and C-178 revealed that both

---

**Table 3 (cont.)**

| Compound | Structure | Ref. |
|----------|-----------|-----|
| BPK-21   | ![Structure](image1) | 175 |
| BPK-25   | ![Structure](image2) | 175 |
| Compound 13 | ![Structure](image3) | 176 |

STING, stimulator of interferon genes.
the nitro group and the furan moiety were essential for the activity of the compounds. Compounds C-176 and C-178 were found to be specific for mouse STING; however, introduction of butyl and hexyl alkyl groups at the 4-position of the phenyl ring (C-170 and C-171, respectively) showed activity against both human and mouse STING.

**Indole ureas (H-151).** A second screen of a 30,000-member library using HEK293T cells expressing human STING led us to identify the 3-acylamino indole derivative H-151 (Ref. 13). We showed that H-151 is active against human and mouse STING, as evidenced by reduction of type I interferons in response to HSV-2 infection in both THP-1 cells and in BMDMs. The authors showed that NO2-OA alkylation both Cys88 and Cys91, residues of STING that are both subject to palmitoylation. Structures shown: cGAS catalytic domain (CD-cGAS) apo form (Homo sapiens PDB: 4O68); CD-cGAS DNA-bound (H. sapiens PDB: 6CT9); STING full-length apo form (H. sapiens PDB: 6NT5); STING full-length cGAMP-bound (H. sapiens PDB: 6NT5, modelled with Gallus gallus PDB: 6NT7 (front view) or G. gallus PDB: 6NT8 (tetramer side-view)).

**Nitro fatty acids.** Hansen et al. have shown that nitro fatty acids are formed after HSV infection. They showed that endogenous nitro fatty acids (NO2-FA) such as nitrolinoleic acid (NO2-cLA) and nitrooleic acid (NO2-OA) covalently modify STING via a Michael addition into the nitro alkene of the fatty acids. Cell-based studies with NO2-FA led to reduction of type I interferons in response to HSV-2 infection in both THP-1 cells and in BMDMs. The authors showed that NO2-OA alkylation both Cys88 and Cys91, in addition to alkylation of His16, in a non-selective fashion. Additional studies in fibroblasts from patients with SAVI, all bearing the gain-of-function STING-N154S alteration, showed that the increase in pTBK1 was almost completely inhibited by NO2-OA treatment.

**Acrylamides.** Vinogradova et al. used chemical proteomic activity-based protein profiling to map 3,000 cysteines in T cells that were reactive with a library of electrophilic small molecules. Mass-spectroscopic analysis showed that acrylamides BPK-21 and BPK-25 formed adducts with Cys91 of STING, as well as with cysteines of other immune-related proteins. Furthermore, this group showed that BPK-25 inhibited cGAMP-mediated STING in peripheral blood mononuclear cells. The authors presented a model for the binding of these acrylamides to Cys91 of STING.

![Diagram](image-url)
Reviews. Ishikawa, H., Ma, Z. & Barber, G. N. STING regulates human StING ligand-binding domain bound to cGAmp (pDb: 4KSY). Pharmacological drug design at the same time. The figure depicts the structure of the interaction. With regard to the functionality of the HAQ allelic variant, there is controversy, with some studies showing broadly decreased cellular responsiveness towards CDNs, while others have reported no significant difference. It should be noted that the allelic frequency of distinct allelic variants is largely influenced by the ethnicity of the population. As such, R232/HAQ is the dominant allele in East Asians. Several allelic variants of STING (formerly known as TMEM173) can be found in the human population with some appearing to encode stimulator of interferon genes (STING) proteins that have altered function. Compared with the major allele encoded by STING1 (referred to as STING R232), the minor allelic variants harbour single or multiple amino acid changes; these are STING R232H, STING HAQ (R71H, G230A, R293Q), STING AQ (G230A, R293Q) and STING Q293. Both STING R232H and STING R293Q show responsiveness towards 2′,3′ cyclic GMP–AMP (cGAmp) but not to 3′,5′ bacterial cyclic dinucleotides (CDNs). Interestingly, the defect of STING R293Q is mitigated by the additional alteration of residue G230A. It has been speculated that the G230A substitution alters the conformation of the ligand region of STING that clamps on to c–dGAMP and thereby increases the stability of the interaction. With regard to the functionality of the HAQ allelic variant, there is controversy, with some studies showing broadly decreased cellular responsiveness towards CDNs, while others have reported no significant difference. It should be noted that the allelic frequency of distinct allelic variants is largely influenced by the ethnicity of the population. As such, R232/HAQ is the dominant allele in East Asians. Overall, the alleles encoding CDN-sensing-defective variants of STING are present in 10% of Europeans and in as many as 30% of East Asians. Interestingly, HAQ/HAQ is absent from African populations, in which very specific alleles can be found such as AQ/AQ and Q293. Together, the existence of this heterogeneity in STING1 underscores the importance of considering naturally occurring STING variants for both association with disease and pharmacological drug design at the same time. The figure depicts the structure of the human STING ligand-binding domain bound to cGAmp (PDB: 4KSY).

Inhibitors of unknown mechanism

A recent report by Huffman et al. detailed a mechanistic study into the synthesis of a library of butanolide heterodimers. A cell-based phenotypic screen of ~250,000 compounds seeking cGAS–STING pathway inhibitors conducted by this group identified four butanolide heterodimers as hits, including compound 13. THP-1 cells treated with compound 13 showed a reduction in CXCL10 mRNA levels following stimulation with dsDNA, which is indicative of reduced type I interferon induction. Although it was demonstrated that compound 13 could modulate the cGAS–STING pathway, the exact mechanism of action was not described.

Outlook and future perspective

The past few years have seen an explosion of interest in and knowledge about the cGAS–STING pathway, which, as we have discussed above, is a central danger-sensing mechanism of innate immunity. Although much remains to be learned, compelling evidence suggests that the sensing of out-of-context DNA drives activation of cGAS–STING signalling in a broad range of inflammatory disease settings, thereby rationalizing the blockade of this pathway for therapeutic benefit. Undoubtedly, continuing efforts will need to carefully validate clinical implications drawn from animal models to human diseases and to provide more precise knowledge on the causative roles of the cGAS–STING pathway in disease pathogenesis. These efforts will go hand in hand with the advancement of solid biomarkers as well as with the use of conditional mouse models or selective drug-like compounds to monitor and inhibit cGAS–STING pathway activity in mice in vivo or in ex vivo human samples, respectively. Concerning the first aspect, measuring the levels of cGAMP and phosphorylation of Ser366 STING are pathway-specific read-outs that can serve as useful, reactive clinical biomarkers, faithfully reflecting cGAS–STING pathway engagement. As for the second aspect, screening approaches have yielded first compounds with drug-like properties that will be of immense value to complement genetic studies by intervening at different stages along the disease process and allowing us to track efficacy in primary human samples.

At the same time, the existing chemical matter can serve as a valuable basis to develop clinical candidates. A unique aspect of the pathway is that it offers two druggable candidates that operate in series — at least as far as the transduction of DNA-initiated signals is concerned. Whether targeting one over the other may be preferred in terms of improving efficacy or safety profiles is still unclear.

A critical aspect for the future will be to better understand the minimal level of inhibition required for therapeutic benefit. It is possible that strong reduction of the pathway provokes adverse effects in humans by increasing susceptibility to infection. This may be particularly relevant for the treatment of chronic conditions that require repetitive or continuous treatment regimens. Still, the direct targeting of cGAS–STING bears potential benefits over more non-specific and broadly acting anti-cytokine antibodies or compounds targeting key signalling molecules, such as JAK inhibitors or TBK1 inhibitors, as it leaves intact essential compensatory innate immune recognition pathways, most critically the TLR, RIG-like receptor and inflammasome pathways. Moreover, insight from fundamental biology as well as preclinical disease models demonstrates that activation of the cGAS–STING pathway occurs in a highly cooperative manner. Therefore, partial — instead of complete — blockade appears to suffice to confer anti-inflammatory effects, while still allowing for cGAS–STING activity in the context of overt infection. If such a balance could be achieved then the breadth and essentiality of cGAS–STING in inflammation is no longer a liability, but in fact may be its most powerful advantage as it could serve as a therapeutic target of broad utility.

Published online 8 April 2021

Box 2 | Human STING allelic variants relevant for drug targeting

Several allelic variants of STING1 (formerly known as TMEM173) can be found in the human population with some appearing to encode stimulator of interferon genes (STING) proteins that have altered function. Compared with the major allele encoded by STING1 (referred to as STING R232), the minor allelic variants harbour single or multiple amino acid changes; these are STING R232H, STING HAQ (R71H, G230A, R293Q), STING AQ (G230A, R293Q) and STING Q293.

Inhibitors of unknown mechanism

A recent report by Huffman et al. detailed a mechanistic study into the synthesis of a library of butanolide heterodimers. A cell-based phenotypic screen of ~250,000 compounds seeking cGAS–STING pathway inhibitors conducted by this group identified four butanolide heterodimers as hits, including compound 13. THP-1 cells treated with compound 13 showed a reduction in CXCL10 mRNA levels following stimulation with dsDNA, which is indicative of reduced type I interferon induction. Although it was demonstrated that compound 13 could modulate the cGAS–STING pathway, the exact mechanism of action was not described.

Outlook and future perspective

The past few years have seen an explosion of interest in and knowledge about the cGAS–STING pathway, which, as we have discussed above, is a central danger-sensing mechanism of innate immunity. Although much remains to be learned, compelling evidence suggests that the sensing of out-of-context DNA drives activation of cGAS–STING signalling in a broad range of inflammatory disease settings, thereby rationalizing the blockade of this pathway for therapeutic benefit. Undoubtedly, continuing efforts will need to carefully validate clinical implications drawn from animal models to human diseases and to provide more precise knowledge on the causative roles of the cGAS–STING pathway in disease pathogenesis. These efforts will go hand in hand with the advancement of solid biomarkers as well as with the use of conditional mouse models or selective drug-like compounds to monitor and inhibit cGAS–STING pathway activity in mice in vivo or in ex vivo human samples, respectively. Concerning the first aspect, measuring the levels of cGAMP and phosphorylation of Ser366 STING are pathway-specific read-outs that can serve as useful, reactive clinical biomarkers, faithfully reflecting cGAS–STING pathway engagement. As for the second aspect, screening approaches have yielded first compounds with drug-like properties that will be of immense value to complement genetic studies by intervening at different stages along the disease process and allowing us to track efficacy in primary human samples.

At the same time, the existing chemical matter can serve as a valuable basis to develop clinical candidates. A unique aspect of the pathway is that it offers two druggable candidates that operate in series — at least as far as the transduction of DNA-initiated signals is concerned. Whether targeting one over the other may be preferred in terms of improving efficacy or safety profiles is still unclear.

A critical aspect for the future will be to better understand the minimal level of inhibition required for therapeutic benefit. It is possible that strong reduction of the pathway provokes adverse effects in humans by increasing susceptibility to infection. This may be particularly relevant for the treatment of chronic conditions that require repetitive or continuous treatment regimens. Still, the direct targeting of cGAS–STING bears potential benefits over more non-specific and broadly acting anti-cytokine antibodies or compounds targeting key signalling molecules, such as JAK inhibitors or TBK1 inhibitors, as it leaves intact essential compensatory innate immune recognition pathways, most critically the TLR, RIG-like receptor and inflammasome pathways. Moreover, insight from fundamental biology as well as preclinical disease models demonstrates that activation of the cGAS–STING pathway occurs in a highly cooperative manner. Therefore, partial — instead of complete — blockade appears to suffice to confer anti-inflammatory effects, while still allowing for cGAS–STING activity in the context of overt infection. If such a balance could be achieved then the breadth and essentiality of cGAS–STING in inflammation is no longer a liability, but in fact may be its most powerful advantage as it could serve as a therapeutic target of broad utility.

Published online 8 April 2021

1. Ablasser, A. & Chen, Z. J. cGAS in action: expanding roles in immunity and inflammation. Science 363, eaat8657 (2019).
2. Ishikawa, H., Ma, Z. & Barber, G. N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461, 788–792 (2009).
3. Ablasser, A. et al. cGAS produces a 2′–5′-linked cyclic dinucleotide second messenger that activates STING. Nature 498, 380–384 (2013).
4. Diner, E. J. et al. The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep. 3, 1355–1361 (2013).
5. Gao, P. et al. Cyclic [G2′-5′]pA[5′-5′]p is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell 153, 1094–1107 (2013).
6. Zhang, X. et al. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol. Cell 51, 226–235 (2013).
7. Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786–791 (2013).

Together with references 3–5, this study demonstrates that cGAS produces a noncanonical cyclic dinucleotide second messenger molecule.
8. Wu, J. et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cysolic DNA. Science 339, 826–830 (2013).
9. Together with reference 7, this study identifies cGAS as a cytosolic DNA sensor inducing type I interferon signaling by producing the second messenger cGAMP.
10. Albrecht, B. & Golenbock, D.N. Regulation of cGAS and RLR-mediated immunity to nucleic acids. Nat. Immunol. 21, 17–29 (2020).
11. Cohn, D.G., et al. Cyclic GMP-AMP signaling protects bacteria against viral infection. Nature 574, 691–695 (2019).
12. Morehouse, B.R., et al. STING cyclic dinucleotide sensing in bacteria. Nature 586, 429–433 (2020).
13. Together with reference 10, this study identifies a role for cyclic GMP-AMP and STING in anti-phase immunity in bacteria, indicating that the eukaryotic cGAS–STING system arose from an ancient bacterial defense mechanism against phages.
14. Vincent, J. et al. Small molecule inhibition of cGAS reduces interferon expression in primary macrophages from autoimmune mice. Nat. Commun. 8, 750 (2017).
15. This study identifies the first class of small-molecule inhibitors of cGAS.
16. Haag, S.M. et al. Targeting STING with cyclic small-molecule orthosters. Nat. Chem. 5, 269–275 (2013).
17. This study identifies the first covalent small-molecule inhibitors of STING.
18. Yu, L. et al. Cyclic G2′,2′-AMP promotes interferon signaling of STING in cancer. Nat. Commun. 10, 1061 (2019).
19. Morehouse, B.R. et al. STING cyclic dinucleotide activation, hyperactivation, and inhibition. Nat. Commun. 7, 178 (2016).
20. STING polymer structure reveals mechanisms for activation by cyclic dinucleotides.
21. Dobbs, N. et al. Activation by translocation from the ER is associated with infection and autoinflammatory disease. Cell Host Microbe 18, 157–168 (2015).
22. Gao, P. et al. Structure-function analysis of STING. Nat. Commun. 7, 14952 (2016).
23. Ramasastri, J.M. et al. Design of arsobenzimidazolimide STING receptor agonists with systemic activity. Nature 564, 439–443 (2018).
24. Saitoh, T. et al. The Ca2+ sensor STIM1 regulates the type I interferon response by retaining the signaling adaptor STING at the endoplasmic reticulum. Nat. Immunol. 20, 152–162 (2019).
25. Zhang, B.C. et al. STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease. Proc. Natl Acad. Sci. USA 116, 1061–1070 (2019).
26. Together with references 155 and 156, this study delineates the cGAS-STING mechanism underlying cellular senescence and senescence-associated secretory phenotype.
27. Golen, M. F. et al. Signaling strength determines proapoptotic functions of STING. Nat. Commun. 8, 427 (2017).
28. Petreska, J. et al. STING-IRF3 pathway links endoplasmic reticulum stress to mitochondrial apoptosis in early alcoholic liver disease. Proc. Natl Acad. Sci. USA 110, 16544–16549 (2013).
29. Zierhut, C. et al. The cytoplasmic DNA sensor cGAS promotes mitotic cell death. Cell 178, 502–515 e525 (2019).
30. This study describes how prolonged mitotic arrest induces cGAS-mediated cell death independently of transcription induction.
31. Brault, M., Olson, T. M., Martinez, J., Stetson, D. B. & Gewirtz, A. Intracellular acidification sensing triggers necroptosis through synergistic type I IFN and TNF signaling. J. Immunol. 200, 2748–2756 (2018).
32. Tang, J. H. et al. Agonistic STING agonists induce apoptosis in malignant B cells. Cancer Res. 76, 2157–2152 (2016).
33. Gulen, M.F. et al. Signalling strength determines cGAMP bioavailability. Nature 564, 573–579 (2019).
34. This study establishes that cGAMP can be transferred between cells to promote in trans STING activation and antiviral immunity.
35. Chen, Q. et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature 535, 493–498 (2016).
36. Schadt, E. L. Cancer-cell-intrinsic cGAS expression mediates tumor immunogenicity. Cell Rep. 29, 1256–1284 e1257 (2019).
37. Lanken, B. et al. Cutting edge: activation of STING in T cells induces type I IFN responses and cell death. J. Immunol. 199, 597–602 (2017).
38. Albrecher, A. et al. Cis-dinucleotide immunostimulatory activity to bystander cells via the intercellular transfer of cGAMP. Nature 505, 530–534 (2013).
39. This study establishes that cGAMP can be transferred between cells to promote in trans STING activation and antiviral immunity.
40. Chen, Q. et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature 535, 493–498 (2016).
41. Schadt, E. L. Cancer-cell-intrinsic cGAS expression mediates tumor immunogenicity. Cell Rep. 29, 1256–1284 e1257 (2019).
42. Luther, J. et al. Hepatic gap junctions amplify alcohol liver injury by promoting cGAMP-mediated IRF3 activation. Proc. Natl Acad. Sci. USA 117, 11667–11673 (2020).
43. Bridgeman, A. et al. Vesicles transfer the antiviral second messenger STING between cells. Science 349, 1228–1232 (2015).
44. Gentz, A. et al. Identification of innate immune signaling by packaging of cGAMP in viral particles. Science 349, 1232–1236 (2015).
45. Ahn, J. et al. T cell states. Immunology 2021, 1–12 (2021).
46. Luteijn, R. D. et al. SC19A transports immunoreactive cyclic dinucleotides. Nature 573, 434–438 (2019).
47. Ritchie, C., Cordova, A. F., Hess, G. T., Bassik, M. C. & Barb, G. L. SC19A is an importer of cGAMP for cGAS-mediated IRF3 activation. Proc. Natl Acad. Sci. USA 117, 11667–11673 (2020).
48. Bridgeham, A. et al. Vesicles transfer the antiviral second messenger STING between cells. Science 349, 1228–1232 (2015).
49. Ahn, J. et al. T cell states. Immunology 2021, 1–12 (2021).
50. Luteijn, R. D. et al. SC19A transports immunoreactive cyclic dinucleotides. Nature 573, 434–438 (2019).
51. Ritchie, C., Cordova, A. F., Hess, G. T., Bassik, M. C. & Barb, G. L. SC19A is an importer of cGAMP for cGAS-mediated IRF3 activation. Proc. Natl Acad. Sci. USA 117, 11667–11673 (2020).
52. Bridgeham, A. et al. Vesicles transfer the antiviral second messenger STING between cells. Science 349, 1228–1232 (2015).
53. Ahn, J. et al. T cell states. Immunology 2021, 1–12 (2021).
80. Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. *Immunity* 41, 843–852 (2014).

81. King, K. R. et al. Type I interferons fuel a fatal response to mycobacterial infection. *Nat. Med.* 25, 1481–1487 (2017).

82. McHugh, J. et al. Released from dying host cells mediates aluminum adjuvant activity. *Nat. Med.* 17, 996–1002 (2011).

83. Kawane, K. et al. Chronic polyarthritis caused by autoantibodies against nucleosome DNA. *Nature* 557, 57–61 (2018).

84. Harding, S. A. et al. Mitotic progression following DNA damage enables pattern recognition within micronuclei. *Nature* 548, 466–470 (2017).

85. Mackenzie, K. J. et al. cGAS surveillance of micronuclei in keratinocytes promotes innate immunity. *Nature* 548, 461–465 (2017).

86. These two studies unveil the role of micronuclei in cell-intrinsic immune surveillance by cGAS to detect genomic instability.

87. Ivanov, A. et al. Lysosome-mediated processing of chromatin in senescence. *J. Cell Biol.* 202, 129–145 (2013).

88. Crow, Y. J. & Manel, N. Acardi-Goutieres syndrome and the type I interferonopathies. *Nat. Rev. Immunol.* 15, 429–440 (2015).

89. Uggenti, C., Lepelley, A. & Crow, Y. J. Self-awareness: nucelic acid-driven inflammation and the type I interferonopathies. *Curr. Opin. Immunol.* 37, 247–267 (2019).

90. Jeremiah, N. et al. Inherited STING-activating mutations underlie a spectrum of autoimmune-like manifestations. *J. Clin. Invest.* 124, 5516–5520 (2014).

91. Liu, Y. et al. Activated STING in a vascular and pulmonary disease. *N. Engl. J. Med.* 371, 507–518 (2014).

92. Lin, B. et al. A novel STING1 variant causes a recessive form of STING-associated vasculopathy with onset in infancy (SAVI). *J. Allergy Clin. Immunol.* 146, 2104–2108.e6 (2020).

93. Nielsen, S. et al. Dense STING mutations identify a novel region in human STING necessary for the control of type I interferon signaling. *J. Clin. Immunol.* 140, 1405–1416 (2018).

94. Komono, H. et al. Pro-inflammation associated with a gain-of-function mutation (R284S) in the innate immune sensor STING. *Cell Rep.* 23, 1122–1125 (2018).

95. Saldanha, R. G. et al. A mutation outside the demarcation domain causes atypical STING-associated vasculopathy with onset in infancy. *Front. Immunol.* 9, 1535 (2018).

96. Reskittalo, S. et al. Novel TMEM173 mutation and the role of disease modifying alleles. *Front. Immunol.* 10, 2770 (2019).

97. Warner, J. D. et al. STING-associated vasculopathy develops independently of IRF3 in mice. *Science* 359, eaao6047 (2018).

98. Bouis, D. et al. Severe combined immunodeficiency due to a gain-of-function mutation (R284S) in the innate immune sensor STING. *Science* 359, eaao6047 (2018).

99. McCauley, M. E. et al. C9orf72 in myeloid cells suppresses STING-associated inflammation. *Nature* 585, 96–101 (2020).

100. Lu, M. et al. Mutations in C9orf72 lead to abnormal chromatin structure and promotes age-associated inflammation. *Nature* 585, 136–139 (2020).

101. These two studies unveil the role of micronuclei in cell-intrinsic immune surveillance by cGAS to detect genomic instability.

102. Gehreim, N. et al. Oxidative damage of DNA confers protection against DNA-induced strain depression. *PLoS Pathog.* 12, e1005809 (2016).

103. Aareberg, L. D. et al. Interleukin-1α induces mtDNA release via the innate immune adaptor STING. *Mol. Cell. Biol.* 47, 801–815.e806 (2019).

104. Sliter, D. A. et al. Parkin and PINK1 mitigate apoptosis and mtDNA release during cell permeabilisation. *Nat. Rev. Neurosci.* 17, 1254–1276 (2019).

105. Sharma, S. et al. Suppression of systemic autoimmunity by the innate immune adaptor STING. *Proc. Natl Acad. Sci. USA* 117, 120–131 (2020).

106. Yamada, K. et al. Th17-ainduced membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus. *Cell Rep.* 29, 1507–1518 (2019).

107. Lee-Kirsch, M. A. et al. Mutations in the gene encoding cGAS are associated with systemic lupus erythematosus. *Nat. Genet.* 39, 1065–1070 (2007).

108. Namjo, B. et al. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. *Genes Immun.* 12, 470–477 (2011).

109. Sharma, S. et al. Suppression of systemic autoimmunity by the innate immune adaptor STING. *Proc. Natl Acad. Sci. USA* 112, 12172–12177 (2015).

110. Then-uum, A. et al. STING mediates lupus via the activation of conventional dendritic cell maturation and plasmacytoid dendritic cell differentiation. *Science* 323, 101530 (2020).

111. Martinez, J. et al. Noncanonical autophagy inhibits the autophagosome, lupus-like response to dying cells. *Nature* 555, 111–115 (2018).

112. Mavragani, C. P. et al. Expression of long interwspersed nuclear element 1 retroelements and induction of type I interferon in patients with systemic autoimmune disease. *Arthritis Rheumatol.* 69, 2686–2696 (2016).

113. Giese Jr, E. Netting neutrophils activate autoactive B cells in lupus. *J. Immunol.* 200, 3366–3371 (2018).

114. Glass, C. K., Sajio, K., Winner, B., Marchetto, M. C. & Gage, F. H. Mechanisms underlying inflammation in neurodegeneration. *Cell* 140, 918–930 (2010).

115. Nabel, E. J., Chinen, T. M., Turner, K. E. & Smith, A. E. C9orf72 mutations in myeloid cells impair cellular senescence. *Nature* 585, 96–101 (2020).

116. Su, M.-Y., Fromm, S. A., Zencz, R. & Hurley, J. H. Structure of the C9orf72 G quartet complex that is haplosufficient in ALS and FTD. *Nature* 585, 251–255 (2020).

117. Sharma, M. et al. Anatomical barriers to immune responses are a major characteristic of systemic autoimmune disease. *Nat. Genet.* 51, 1736 (2017).

118. Glass, C. K., Sajio, K., Winner, B., Marchetto, M. C. & Gage, F. H. Mechanisms underlying inflammation in neurodegeneration. *Cell* 140, 918–930 (2010).

119. Nabel, E. J., Chinen, T. M., Turner, K. E. & Smith, A. E. C9orf72 mutations in myeloid cells impair cellular senescence. *Nature* 585, 96–101 (2020).

120. Ahn, J. et al. Inflammation-driven carcinogenesis is mediated through STING. *Nat. Commun.* 5, 5166 (2014).

121. Liu, H. et al. Host STING-dependent MDCS mobilization drives extrinsic radiation resistance. *Nat. Commun.* 8, 2173 (2017).

122. Grau-Olave, M., Delgado-Slaven, E., Sanchis, I., Sanz-Rodriguez, M. J. & Sanz, J. C. Cyclic GMP-AMP synthase promotes the inflammatory and autoreactive responses in hereditary stones. *Nat. Genet.* 51, 131–136 (2019).

123. van Deursen, J. M. The role of senescent cells in age-related diseases. *Nature* 509, 439–446 (2014).

124. Baker, D. J. et al. Naturally occurring p16(+)-positive cells shorten healthy lifespan. *Nature* 530, 184–189 (2016).

125. Ueda, H. et al. Atoh1 induces DNA repair and promotes tumorigenesis. *Nature* 563, 131–136 (2019).

126. van Deursen, J. M. The role of senescent cells in age-related diseases. *Nature* 509, 439–446 (2014).

127. Baker, D. J. et al. Naturally occurring p16(+)-positive cells shorten healthy lifespan. *Nature* 530, 184–189 (2016).

128. Ueda, H. et al. Atoh1 induces DNA repair and promotes tumorigenesis. *Nature* 563, 131–136 (2019).

129. van Deursen, J. M. The role of senescent cells in age-related diseases. *Nature* 509, 439–446 (2014).

130. Baker, D. J. et al. Naturally occurring p16(+)-positive cells shorten healthy lifespan. *Nature* 530, 184–189 (2016).
157. Simon, M. et al. L1NE1 derepression in aged wild-type and SIRT6-deficient mice drives inflammation. Cell Metab. 29, 871–885 e875 (2019).

158. Childs, B. G. et al. Senescent cells: an emerging target for diseases of ageing. Nat. Rev. Drug Disc. 16, 718–735 (2017).

159. Desdín-Micó, G. et al. T cells with dysfunctional mitochondria induce mitonemalitosis and premature senescence. Science 368, 1371–1376 (2020).

160. Hall, J. et al. Discovery of PF-06982815 as a high affinity inhibitor of c-GAS enabled by a novel fluorescence polarization assay. PLoS ONE 12, e0184835 (2017).

161. Lima, L. et al. Development of human cGAS-specific small-molecule inhibitors for repression of dsDNA-triggered interferon expression. Nat. Commun. 10, 2261 (2019).

162. Paullina-Salinas, R. et al. Discovery of small-molecule cyclic GMP-AMP synthase inhibitors. J. Org. Chem. 85, 1579–1600 (2020).

163. Zhao, W. et al. cGAS-mediated stabilization of IFI16 promotes innate signaling during herpes simplex virus infection. Proc. Natl Acad. Sci. USA 112, E1773–E1781 (2015).

164. Gentili, M. et al. The N-terminal domain of cGAS determines preferential association with centromeric DNA and innate immune activation in the nucleus. Cell Rep. 26, 5798 (2019).

165. Volkman, H. E., Cambier, S., Gray, E. E. & Stetson, D. B. Tight nuclear tethering of cGAS is essential for preventing autoactivity. elife 8, e47491 (2019). This study shows that cGAS is predominantly a nuclear protein and that cGAS is tethered to chromatin.

166. Guey, B. et al. BAF restricts cGAS on nuclear DNA to prevent innate immune activation. Science 369, 823–828 (2020).

167. Boyer, J. A. et al. Structural basis of nucleosome-dependent cGAS inhibition. Science 370, 450–454 (2020).

168. Kujrja, T. et al. Structural basis for the inhibition of cGAS by nucleosomes. Science 370, 455–458 (2020).

169. Michalski, S. et al. Structural basis for sequestration and autoinhibition of cGAS by chromatin. Nature 587, 678–682 (2020).

170. Pathare, G. R. et al. Structural mechanism of cGAS inhibition by the nucleosome. Nature 587, 668–672 (2020).

171. Zhao, B. et al. The molecular basis of tight nuclear tethering and inactivation of cGAS. Nature 587, 673–677 (2020). These five studies report the cryo-EM structure of cGAS tethered to nucleosomes and identify how cGAS is inactivated when bound to the nucleosome.

172. Uggetti, C. et al. cGAS-mediated induction of type I interferon due to inborn errors of histone pre-mRNA processing. Nat. Genet. 52, 1364–1372 (2020).

173. Yu, G. et al. Single nucleotide polymorphisms of human STING can affect innate immune response to cyolic dinucleotides. PLoS ONE 8, e78463 (2013).

174. Patel, S. et al. The common R71H-G230A-R295Q human TMEM175 is a null allele. J. Immunol. 198, 776–787 (2017).

175. Sivick, K. E. et al. Comment on ‘The common R71H-G230A-R295Q human TMEM175 is a null allele’. J. Immunol. 198, 4185–4188 (2017).

176. Patel, S. & Jin, L. TMEM175 variants and potential importance to human biology and disease. Genes Immun. 20, 82–89 (2019).

177. Zhou, W. et al. Structure of the human cGAS-DNA complex reveals enhanced control of immune surveillance. Cell 174, 300–311 e311 (2018).

178. Rice, G. I. et al. Assessment of interferon-related nucleosome-DSB biomarkers in Aicardi-Goutieres syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol. 12, 1159–1169 (2013).

179. Mackenzie, K. J. et al. Ribonuclease H2 mutations induce a cGAS-STING-dependent innate immune response. EMBO J. 35, 831–844 (2016).

180. Pokatayev, V. et al. RNAse H2 catalytic core Aicardi-Goutieres syndrome-related mutant invokes cGAS- STING innate immune-sensing pathway in mice. J. Exp. Med. 213, 529–536 (2016).

181. Konig, N. et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann. Rheum. Dis. 76, 468–472 (2017).

182. Wang, J. et al. Accumulation of cytosolic dsDNA contributes to fibroblast-like synergocytosis-mediated rheumatoid arthritis synovial inflammation. Int. Immunopharmacol. 76, 105791 (2019).

183. Li, Q. et al. Inhibition of double-strand-DNA-sensing cGAS ameliorates brain injury after ischemic stroke. EMBO Mol. Med. 12, e11002 (2020).

184. Kerur, N. et al. cGAS drives noncanonical-inflammation activation in age-related macular degeneration. Nat. Med. 24, 50–61 (2018).

185. Zhao, Q., Wei, Y., Pandol, S. J., Li, L. & Habtezion, A. STING signaling promotes inflammation in experimental acute pancreatitis. Gastroenterology 154, 1822–1835 e1822 (2018).

186. Bennerzorzog, S. et al. STING-dependent sensing of self-DNA drives silica-induced lung inflammation. Nat. Commun. 9, 1–19 (2018).

187. Hegertz, E. L., Harper, J. & Walker, W. E. STING and TNF contribute to mouse sepsis, depending on severity of the disease model. Shock 47, 621–631 (2017).

188. Zeng, L. et al. ALK is a therapeutic target for lethal sepsis. Sci. Transl. Med. 9, eaan5689 (2017).

189. Cao, D. et al. Cytosolic DNA sensing promotes macrophage transformation and governs myocardial ischemic injury. Circulation 137, 2613–2634 (2018).

190. Hu, D. et al. Cytosolic DNA sensor cGAS plays an essential pathogenetic role in pressure overload-induced heart failure. Am. J. Physiol. Heart Circ. Physiol. 318, H1525–H1537 (2020).

191. Zhu, Q. et al. Cutting edge: STING mediates protection against coloectal tumorigenesis by governing the magnitude of intestinal inflammation. J. Immunol. 193, 4779–4782 (2014).

192. Abdullah, A. et al. STING-mediated type-I interferons contribute to the neuroinflammatory process and detrimental effects following traumatic brain injury. J. Neuroinflammation 15, 323 (2018).

Acknowledgements
The authors thank W. R. Roush and H. M. Seidel for advice during the preparation of this document. A.A. acknowledges support from the SNF (150034) and the European Research Council (ERC-SG: 804935).

Author contributions
The authors contributed equally to all aspects of the article.

Competing interests
A.A. is a member of the scientific advisory board of IFM Therapeutics and scientific co-founder of IFM Due. J.D.K. and S.V. are employees of IFM Therapeutics. A.D. declares no competing interests.

Peer review information
Nature Reviews Immunology thanks P.L. and N. Van for their contribution to the peer review of this work.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© Springer Nature Limited 2021